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ABSTRACT 
Newnum, America Bethanne. M.S., Purdue University, August 2012. Bone Metabolism: 
The Role of STAT3 and Reactive Oxygen Species. Major Professor: Jiliang Li. 
 
 
Signal Transducers and Activators of Transcription 3 (STAT3), a transcription factor 
expressed in many cell types, including osteoblasts and osteoclasts, is emerging as a key 
regulator of bone mass and strength. STAT3 mutations cause a rare human 
immunodeficiency disease characterized by extremely elevated levels of IgE in serum 
that have associated craniofacial and skeletal features, such as reduced bone mineral 
density and recurrent pathological fractures. Our microarray data and 
immunohistochemical staining using a normal rat model have shown that STAT3 mRNA 
and protein levels markedly increase in response to mechanical loading. In addition, as 
indicated by STAT3 phosphorylation in MC3T3-E1 osteoblastic cells, STAT3 activity 
significantly increases in response to 30 to 90 minutes fluid shear stress. In order to 
further study the role that STAT3 plays in bone responsiveness to loading, tissue-
selective STAT3 knockout (KO) mice, in which inactivation of STAT3 occurs in 
osteoblasts, were generated by breeding the transgenic mice in which Cre recombinase 
cDNA was cloned downstream of a 3.6 or 2.3 kb fragment of the rat Col1a1 promoter 
(Col3.6-Cre and Col2.3-Cre, respectively) with a strain of floxed mice in which the two 
loxP sites flank exons 18-20 of the STAT3 gene were used. Mice engineered with bone  
xi 
 
xi 
selective inactivation of STAT3 in osteoblasts exhibited significantly lower bone mineral 
density (7-12%, p<0.05) and reduced ultimate force (21-34%, p<0.01) compared to their 
age-matched littermate controls. The right ulnae of 16-week-old bone specific STAT3 
KO mice and the age-matched control mice were loaded with peak forces of 2.5 N and 
2.75 N for female and male mice, respectively, at 2 Hz, 120 cycles/day for 3 consecutive 
days. Mice with inactivation of STAT3 specific in bone were significantly less 
responsive to mechanical loading than the control mice as indicated by decreased relative 
mineralizing surface (rMS/BS, 47-59%, p<0.05) and relative bone formation rate 
(rBFR/BS, 64-75%, p<0.001). Bone responsiveness was equally decreased in mice in 
which STAT3 is inactivated either in early osteoblasts (Col3.6-Cre) or in mature 
osteoblasts (Col2.3-Cre).  
Accumulating evidence indicates that bone metabolism is significantly affected by 
activities in mitochondria. For instance, although STAT3 is reported to be involved in 
bone formation and resorption through regulation of nuclear genes, inactivation of 
STAT3 is shown to disrupt mitochondrial activities and result in an increased level of 
reactive oxygen species (ROS). Inactivation of STAT3 suppressed load-driven 
mitochondrial activity, which led to an elevated level of ROS in cultured primary 
osteoblasts. Oxidative stress induced by administration of buthionine sulfoximine (BSO) 
significantly inhibits load-induced bone formation in wild type mice. Taken together, the 
results support the notion that the loss-of-function mutation of STAT3 in osteoblasts and 
osteocytes diminishes load-driven bone formation and impairs the regulation of oxidative 
stress in mitochondria. 
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CHAPTER 1. INTRODUCTION 
1.1 
There are two main types of bone: cancellous (also called trabecular or spongy) bone, and 
cortical, or compact, bone. Cancellous bone is weaker than cortical bone, with a higher 
surface area. Bone tissue has three main types of cells: osteoblasts, osteocytes, and 
osteoclasts. Osteoblasts are specialized bone cells that build bone by secretion of a matrix 
called osteoid. When osteoblasts become trapped in this material, they become 
osteocytes, the most abundant cells in bone. Osteocytes maintain the general metabolism 
of bone tissue. Osteoclasts are the third type of specialized bone cell; they mediate bone 
resorption. There are two main transformative processes in bone: modeling and 
remodeling. Bone modeling occurs when bone formation and resorption occur on 
separate surfaces, is responsible for gain in skeletal mass, and occurs mainly during 
growth. On the other hand, bone remodeling occurs continuously. Osteoclasts and 
osteoblasts function together in bone remodeling. In normal bone function, both 
osteoclasts and osteoblasts are active in a homeostasis to optimize bone health (1).  
Bone Cells and Bone Homeostasis 
 
2 
 
2 
1.2 
There are two ways that the skeleton hardens, or ossifies, during the embryonic formation 
of bone. The first, and by far the most common, is endochondrial ossification. In this 
process, a template made of cartilage is initially laid down in the shape of the bone to be 
made. This template will eventually be replaced by true bone. Intramembranous 
ossification, on the other hand, involves formation of bone directly from osteoblasts, and 
only takes place in rare instances (2). 
Ossification of the Skeleton 
 
1.3 
Osteoclasts, the cells responsible for bone resorption, are derived from 
monocyte/macrophage precursors (3). These precursors migrate into bone, divide, and 
differentiate into tartrate resistant acid phosphatase (TRAP) positive cells. They then fuse 
to become multinucleated cells while invading the bone shaft, thus forming the bone 
marrow cavity (2). 
Osteoclast Differentiation and Proliferation 
 
Although osteoclasts and osteoblasts have opposite functions, osteoclast differentiation is 
partially regulated by osteoblasts. Osteoclast precursor cells express receptor activator of 
nuclear factor κ B (RANK), which interacts with RANK ligand (RANKL); RANKL is 
expressed on several cell types, including osteoblasts. The cytokines interleukin 6 (IL6) 
and IL11 have been shown to increase osteoclastogenesis and, in turn, bone resorption 
(4). Glycoprotein 130 (Gp130), a common receptor subunit for many cytokines such as 
IL6 and IL11, is also present on osteoblasts (5). Macrophage colony stimulating factor 
(M-CSF) derived from stromal cells also plays a role in osteoclast differentiation (6). 
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ROS derived from mitochondria have also been shown to have a role in osteoclast 
formation (7). 
 
1.4 
Mechanotransduction plays a crucial role in physiology of many tissues including bone. 
The mass and architecture in bones are governed, to some extent, by adaptive 
mechanisms sensitive to their mechanical environment. Fluid shear stress (FSS) is 
generated by the movement of interstitial fluid due to mechanical stimulation (8).  
Osteoblasts as well as their precursors are stimulated to proliferate and differentiate by 
FSS (9).  This FSS-stimulated osteoblast activity also activates osteogenic genes, such as 
Osteoprotegrin, Msx2, and Runx2 (10). These genes that respond to mechanotransduction 
are often referred to as mechanosensitive genes. A process called mechanical loading can 
be used to simulate exercise in mice; this stimulates bone remodeling and osteoblasts to 
form new bone (11). 
Mechanotransduction 
 
1.5 
When one type of cell becomes more active than the other, the homeostasis is disturbed, 
which can lead to disease. Osteoporosis, one of these pathological conditions, is 
characterized by higher osteoclast and lower osteoblast activity. These cellular events 
lead to lower bone mass (1). Due to cancellous bone being weaker and having more 
surface area than cortical bone, cancellous bone is more affected by osteoporosis. As 
previously described, RANKL is an important factor in osteoclast differentiation, and can 
play a key role in osteoporosis, which has led to the development of a monoclonal 
Disruptions in Bone Homeostasis 
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antibody for use in human osteoporosis patients (12). On the other hand, osteopetrosis is 
a lowered activity of osteoclasts due to genetic factors. Although osteopetrosis is rare 
compared to osteoporosis, it can be very serious; the autosomal recessive form is 
typically lethal within the first 10 years of life (13).  
 
1.6 
STATs (Signal Transducers and Activators of Transcription) are cytoplasmic factors that, 
when activated, transcribe many genes that are necessary for widely varying cellular 
processes. Seven STAT genes are present in mammals: STATs 1, 2, 3, 4, 5a, 5b, and 6. 
The STATs function as dimers, which can be either hetero- or homodimers, and play 
varied roles in cellular function (14). 
STATS 
 
1.7 
Cytosolic STAT3 has various roles in the cell, and has been shown to be necessary for 
the development of visceral endoderm in mouse embryos. In fact, STAT3 knockout 
embryos begin to disintegrate at the precise time that STAT3 expression would normally 
begin in the embryo between 6.5 and 7.5 days (15). STAT3 has also been proven 
necessary to maintain mouse embryonic stem cells in an undifferentiated state (16). In a 
conditional knockout of STAT3 where the gene was deleted in bone marrow and 
endothelial cells, a condition similar to Crohn’s disease was reported. All of these mice 
were deceased by 8 weeks. As Crohn’s disease most likely has an immune component, 
this suggests that STAT3 plays a role in immunity (17). When activated by leptin, 
Cytosolic STAT3 
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STAT3 aids in cell survival in hippocampal neurons, and also mediates mitochondrial 
stabilization (18). 
 
Cytosolic STAT3 is activated by phosphorylation by IL6 and various other cytokines and 
growth factors (19). This process involves activating the JAK/STAT pathway and turns 
on many different types of genes, of which some are vital for survival. The process of 
tyrosine phosphorylation of STAT3 (and other STATs) is accomplished by the Janus 
Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway. In the 
case of STAT3, IL6 binds to its receptor, which activates JAK1 and JAK2, which is 
phosphorylated on a tyrosine, residue 1138 (Y1138) (18). This produces a docking site 
where STAT3 is phosphorylated on Y705. Two phosphorylated STAT3 molecules 
dimerize due to interaction of Y705 with the SH2 domain on the other STAT3 molecule; 
the dimer then relocates to the nucleus to transcribe genes containing GAS (γ-interferon 
activation sequence) elements, also called SIEs (sis-inducible element), which have the 
DNA sequence of 5’-TT(N)4-6AA-3’ (20). 
 
STAT3 interacts with many different proteins; a very important one is GRIM-19. GRIM-
19 plays a role in interferon-β and retinoic acid induced cell death, promoting apoptosis. 
GRIM-19 is also found in the hydrophilic arm of complex I, subunit 1λ (21). Residues 
36-72 on GRIM-19 interfere with the DNA binding and linker domains of STAT3; this 
suggests that GRIM-19 prevents STAT3 from binding to DNA, thus preventing the 
transcription of STAT3 dependent genes. This antagonizes STAT3’s anti-apototic role 
(19). Due to GRIM-19 having a dual role in both the cytoplasm/nucleus and in complex I 
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of the electron transport chain, and the strong association of GRIM-19 and STAT3, it was 
thought that STAT3 might also be present in the electron transport chain. Gp130, a 
receptor subunit previously mentioned in connection with IL6 and IL11, typically 
activates STAT3 (22). 
 
1.8 
Hyper-IgE syndrome, also called Job’s syndrome, is caused by mutations in the STAT3 
gene. Although there are several places in the STAT3 gene that can contain mutations, 
the two areas in the gene that mutate the most commonly are the SH2 domain and the 
DNA binding domain (23). This disorder causes immunity and connective tissue to be 
abnormal, and is autosomal dominant. It also causes marked scoliosis, abnormal bone 
formation, and bowed legs.  
Diseases Associated with STAT3 Mutation 
 
1.9 
Mitochondrial STAT3 was found due to the co-localization of STAT3 and GRIM-19. It 
was also verified that the STAT3 found was not a cytoplasmic contaminant. 
Mitochondrial STAT3 (mSTAT3) has been shown to be located in either the inner 
mitochondrial membrane or in the matrix rather than the outer mitochondrial membrane 
(24). 
Mitochondrial STAT3 
 
Specifically, mSTAT3 is located in complex I of the electron transport chain. There is 
also evidence to suggest that mSTAT3 is either also located in complex II of the electron 
transport chain, or in a location where complex I and complex II interact. This is thought 
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to be a possibility due to the facts that the complex II Fp subunit co-precipitates with 
complex I, and STAT3 knockouts have greatly diminished complex II function. Being a 
component of complex I in the electron transport chain, mitochondrial STAT3 plays a 
role in cellular respiration. The activity of complexes I and II in murine pro-B cells was 
decreased significantly; complexes III and IV were not affected (24). 
 
Unlike cytosolic STAT3, mSTAT3 is predominantly phosphorylated on S727 rather than 
Y705. When compared to whole cell extracts, the ratio of total STAT3 to serine 
phosphorylated STAT3 was 2.5, in cytosolic extracts it was 2.3, and in mitochondrial 
extracts it was 0.3, indicating a strong presence of serine phosphorylated STAT3 in 
mitochondria. mSTAT3 is also thought to be present as a monomer instead of a dimer, 
due to the lack of interaction with another STAT3 molecule at the SH2 domain (24). 
 
STAT3 is phosphorylated on S727 by the MAPK family of serine kinases. These 
recognize a conserved PMSP (Proline-Methionine-Serine-Proline) sequence on the C-
terminal end of the protein. There are many MAPKs, and the one that phosphorylates 
mSTAT3 is not clear. However, several MAPKs have been shown to phosphorylate 
cytosolic STAT3 on the S727 residue, including ERK, p38, PKCδ,  and JNK1 (25). 
 
Due to its role in mitochondria, STAT3 is especially vital in types of cells with high 
energy needs, such as osteoblasts and osteoclasts in bone. O2 consumption is increased 
when ascorbic acid is added to force cells to differentiate into osteoblasts, and ATP 
8 
 
8 
release is also increased when precursors differentiate into osteoblasts (24). This shows 
that osteoblasts have higher energy needs than the cells from which they are derived. 
 
1.10 
Mitochondria are large organelles that contain two membranes; an outer membrane, 
which makes up the external surface, and an inner membrane, which is folded into 
structures called cristae. In between these two membranes is an intermembrane space, 
and inside the inner membrane is where the mitochondrial matrix is located (1). 
Mitochondria 
 
Mitochondria have their own DNA (mtDNA), separate from the nuclear genome, which 
is located in the matrix. In most multicellular animals, this DNA is in the form of 
multiple copies of a circular molecule similar to a bacterial plasmid. MtDNA is 
cytoplasmically inherited, and is thus 99.99% inherited from the mother (1). Although 
mtDNA is mostly in circular form, it can also be linear in some organisms, and it can also 
vary greatly in size. MtDNA ranges in size from 6 kb in Plasmodium to 2 Mb in melon 
and cucumber. Mitochondrial genomes can code for anywhere between 7 and 37 genes. 
These genes are very important to the cell; in fact, large deletions of mitochondrial DNA 
can cause diseases such as chronic progressive external opthalmoplegia and Kearns-Sayre 
syndrome, both of which cause eye defects. Vertebrate mitochondrial DNA is 16.5 kb 
(26) and encodes 2 mitochondrial RNAs (12S RNA and 16S RNA), 22 tRNAs used to 
translate mitochondrial RNAs, and 13 proteins integral to ATP synthesis and the electron 
transport chain (ND1-ND6, ND4L, Cytochrome b, CO I-III, ATPase 6, and ATPase 8 
(26)). Another difference between mtDNA and nuclear DNA is in the genetic code. In a 
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few instances, codons in mitochondrial DNA code for different proteins than in nuclear 
DNA (1). 
 
1.11 
Mitochondria are essential to cellular function due to their production of adenosine 
triphosphate, or ATP, the energy currency of the cell. The synthesis of ATP is facilitated 
by redox reactions inside the mitochondria, where electrons are transferred between 
molecules; one molecule loses electrons (oxidation), and the other molecule gains 
electrons (reduction). In some cases, hydrogen atoms are transferred at the same time. 
The energy released in these reactions can be used to produce ATP (1). 
Mitochondrial Function 
 
1.12 
The first complex of the electron transport chain (ETC), also called NADH-CoQ 
reductase, functions to shuttle two electrons from NADH to CoQ. First, the electrons 
move from NADH to flavin mononucleotide (FMN), a cofactor related to FAD. FMN is 
non-covalently bound (27), and can accept two electrons, but does so one at a time. The 
two electrons are then transferred to one of several (28) iron-sulfur clusters, then to CoQ. 
This process oxidizes NADH to NAD+; the function of Complex I can be investigated by 
measuring the ratio of NAD+ to NADH. This process also reduces CoQ to CoQH2. This 
CoQH2 is then transferred to Complex III. The energy released pumps 4 protons into the 
intermembrane space, beginning to establish the proton gradient which will later be used 
for ATP (1). 
Complexes of the ETC 
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Succinate dehydrogenase, the enzyme that converts succinate to fumarate in the citric 
acid cycle, also plays a role in electron transport; it is one of the four subunits of complex 
II of the ETC, succinate-CoQ reductase (1). The two electrons released during the 
conversion of succinate to fumarate are transferred to FAD, which is located in succinate 
dehydrogenase. The electrons are then transferred through a series of iron-sulfur clusters, 
which regenerate FAD, and then the electrons are transferred to CoQ that has bound to a 
cleft in complex II on the matrix side. The CoQH2 formed is then transferred to complex 
III (1). 
 
Complex III  functions as a dimer. Complex III accepts two electrons from CoQH2, thus 
regenerating CoQ, and simultaneously pumps two protons from the matrix into the 
intermembrane space..The energy of this process is coupled to the pumping of two 
protons into the intermembrane space and the reduction of a molecule of cytochrome c. 
CoQH2 then dissociates, allowing another molecule of CoQ to bind (28). 
 
Complex IV, also called cytochrome c oxidase, has the main function of reducing 
cytochrome c. Cytochrome c first transfers each electron from its heme group to Cua2+, a 
pair of copper ions in complex IV. The electron then moves to the heme group of 
cytochrome a, then to Cub2+ and then to the heme in cytochrome a3; these two structures 
make up the oxygen reduction center. The electrons are then passed to O2, the final 
acceptor, forming water. Four protons are also pumped into the intermembrane space; the 
mechanism for this process is not known (1). 
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ATP synthase, also called Complex V, functions to manufacture ATP from ADP and Pi, 
using the protons pumped into the intermembrane space by the first four complexes of the 
ETC (1). It can also hydrolyze ATP to pump protons against an electrochemical gradient 
(28). 
1.13 
Reactive Oxygen Species (ROS) are a type of free radical derived from oxygen, and are 
produced by many bodily functions, including oxidative phosphorylation that occurs in 
mitochondria (29). ROS antagonize Wnt signaling, which is important for 
osteoblastogenesis, by diverting beta catenin to Forkhead box O mediated transcription 
(30). ROS have also been shown to help induce osteoclast activation, and they are also 
formed by osteoclasts (31). Thus, in several different ways, ROS serve to decrease bone 
formation and increase bone resorption, increasing the likelihood of osteoporosis. ROS 
are a type of oxidant; these compounds cause cellular stress when they are in abundance. 
Antioxidants combat the action of the oxidants (32). 
ROS 
 
1.14 
Glutathione, an antioxidant, fights cellular damage from ROS by serving as an electron 
donor. This process converts glutathione to glutathione sulfide. As cells age, this process 
becomes less efficient, and damage from ROS becomes more pronounced (33). 
Buthionine sulfoximine, or BSO, blocks a key step in the synthesis of glutathione, thus 
decreasing glutathione levels (Slivka, 1988). This is thought to increase ROS levels, and 
thus, oxidative damage; osteonecrosis has been reported in rats when glutathione 
depletion was achieved using BSO (34). 
Glutathione and BSO 
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1.15 
γ-glutamylcysteine synthetase is the enzyme that catalyzes the first step in GSH synthesis 
(35). In this step, glutamic acid is bound to cysteine, forming γ-glutamylcysteine. This is 
the rate-limiting step in GSH synthesis (36). In the second step, glycine is added to the 
compound to form glutathione. BSO is an inhibitor of γ-glutamylcysteine synthetase (35) 
thus blocking the key, rate-limiting step in this reaction. 
Glutathione Synthesis Pathway 
 
1.16 
We hypothesized that the lack of STAT3 in osteoblasts and osteocytes would cause lower 
bone formation after mechanical loading. To test this, we deleted exons 18-20 of the 
STAT3 gene specifically in early murine osteoblasts, and performed mechanical loading. 
We also hypothesized that STAT3 deficient osteoblasts would produce more ROS than 
control osteoblasts. We tested this by isolating osteoblasts from both control and KO 
mice, and assaying for ROS. We also hypothesized that administration of BSO would 
cause lower bone formation after mechanical loading. We tested this by injecting mice 
with two doses of BSO, performing mechanical loading, and measuring bone formation 
parameters. 
Research Goals 
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CHAPTER 2.  MATERIALS AND METHODS 
2.1 
In conventional knockout mice, the gene of interest is eradicated from the entire organism. 
Although this method can be useful in some cases, there are others where it is not feasible, 
such as when the protein made by the gene of interest is vital for survival. Thus, it is very 
valuable to be able to selectively knock out a gene in just one type of cell. This is also 
helpful in evaluating the loss of that gene in the specific cell type. The cre/loxP system is 
a method to accomplish this goal. The recombinase Cre is inserted into the genome of a 
line of mice; this gene is controlled by a cell-specific promoter unique to the type of cell 
that will be targeted for gene knockout. Another line of mice are created with the gene of 
interest located between two loxP sites. These loxP sites are recognized by the Cre 
recombinase when the two lines of mice are bred together, thus excising the gene of 
interest. The cell-specific promoter ensures that the gene is only knocked out in the 
desired cell type. Using this system, many different conditional knockouts can be made 
(37). In our case, we used mice with exons 18-20 flanked by two loxP sites (Figure 1). 
These exons code for the SH2 domain in STAT3, which is the region that is often 
mutated in diseases of STAT3 deficiency. The cell-specific promoter used was a 3.6 kb 
fragment of the collagen I promoter; using this promoter serves to target early osteoblasts, 
which in turn eliminates functional STAT3 in late osteoblasts and
Cre/LoxP Methodology 
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osteocytes as well. After Cre recognizes the loxP sites and excises exons 18-20 of STAT3, 
exons 17 and 21 are joined with a loxP site in between; exons 18-20 circularize, and 
contain the other loxP site in between exons 18 and 20. These mice were then denoted 
Col3.6-Cre;STAT3flox/flox mice, with their control littermates being denoted Col3.6-
Cre;STAT3+/+ mice. 
2.2 
For the STAT3 study, STAT3 bone specific knockout mice were made using the 
Cre/LoxP system by breeding Cre recombinase mice (driven by a 3.6 kb fragment of the 
collagen I promoter) and floxed STAT3 mice. The Cre recombinase transgenic mice were 
provided by Dr. Barbara Kream of the University of Conneticut Health Center; the floxed 
STAT3 mice were provided by Dr. Xin-Yuan Fu of the Department of Microbiology and 
Immunology of the Indiana School of Medicine. Animals homozygous for LoxP STAT3 
and had at least one copy of the Cre gene were considered conditional knockouts; animals 
who were wild type STAT3 and had at least one copy of the Cre gene were considered 
controls. For the BSO study, C57/BL6 female mice were purchased from Harlan 
Laboratories and allowed to mature to 16 weeks before injections of BSO were 
administered. All procedures were performed in accordance with the IUCUC guidelines. 
Animal Breeding 
 
2.3 
To perform genotyping, tail snips were obtained from the mice, and the DNA was 
isolated. The lysis buffer contained 40 mm Tris (pH 8.0), 50 mm KCl, 2.5 mM EDTA, 
0.4% NP-40, 0.45% Tween-40.  40 µl of proteinase K (stock 10 mg/ml) was added to the 
lysis buffer immediately before use; 100 µl of this solution was used per tail snip. This 
Genotyping 
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was incubated overnight in a 56 degree C waterbath. The next morning the samples were 
incubated in a dry bath for 10 minutes at 95 degrees to inactivate proteinase K, and the 
lysate was diluted with 100 µl of autoclaved DI water. 1 µl of this solution was then used 
for PCR. PCR was performed using primers for both Cre and STAT3. The sequences for 
the Cre primers are as follows: GAGTGATGAGGTTCGCAAGA (Cre-1); 
CTACACCAGAGACGGAAATC (Cre-2). If positive for Cre, those samples showed a 
615 bp size band when run on an agarose gel. If mice were negative for Cre, there was no 
band, due to Cre not normally being present in mammalian cells. The sequences for the 
STAT3 primers are as follows: ATTGGAACCTGGGACCAAGTGG (STAT3 Forward); 
ACATGTACTTACAGGGTGTGTGC (STAT3 Reverse). For STAT3, the WT band was 
480 bp, and the floxed band was 520 bp. If an individual mouse was heterozygous, it 
showed two faint bands very close together. If the genotyping was successful, there were 
always bands for each sample for STAT3 due to it being constitutively expressed in 
mammalian cells. Since Cre recombinase was driven by an osteoblast-specific promoter, 
its expression will be limited to bone tissue, and thus exons 18-20 of STAT3 will only be 
excised in these specific cells. 
 
2.4 
In the STAT3 study, 16 week old mice were subjected to axial loading of the right ulna 
for 120 cycles at 2 hertz, for three consecutive days, using an electromagnetic actuator 
(Bose ElectroForce 3200 series; EnduraTEC). The procedure was performed under 
general anesthesia, using 3-5% isoflurane (Sigma-Aldrich, St. Louis, MO). The peak 
force used for males was 2.75 N, and for females the peak force used was 2.5 N. The 
Mechanical Loading 
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difference in peak forces for males and females was chosen to ensure that all specimens 
experienced similar peak strains during loading. The peak strains experienced by wild 
type mice, both male and female, was approximately 2800 microstrains at the ulna 
midshaft. For conditional STAT3 knockout mice, the peak strains experienced by both 
male and female mice ranged between approximately 2940 and 2970 microstrains. The 
left ulnas were not loaded, and served as internal controls. Calcein was injected 5 days 
after the first loading bout, and alizarin was injected 9 days after the first loading bout. 
These injections were administered interperitoneally. Both the right and left ulnas were 
processed for histomorphometry to evaluate bone formation as a result of mechanical 
loading; femurs were also collected to determine bone size, bone mineral density and 
mechanical properties.  
 
In the BSO study, to investigate the role of oxidative stress in bone mechano-
responsiveness in vivo, we injected female C57BL6 mice with BSO at doses of 800 and 
1600 mg/kg 2 hours before we applied mechanical loading using an ulna loading 
modality with 16-week-old mice using an electromagnetic actuator (Bose ElectroForce 
3200 series; EnduraTEC). Subcutaneous injection of BSO to mice leads to a peak tissue 
level after 2 hrs, coincident with the loading session. BSO blocks a key enzyme in 
glutathione synthesis and causes a rise in ROS level. The loading conditions were: 120 
cycles/day, 3 consecutive days, 2 Hz cycle frequency, with peak forces of 2.6 N. The 
non-loaded left forearms served as an internal control. The procedure was performed 
under general anesthesia, using 3-5% isoflurane (Sigma-Aldrich, St. Louis, MO). Calcein 
was injected 5 days after the first loading bout, and alizarin was injected 9 days after the 
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first loading bout. These injections were administered interperitoneally. Both the right 
and left ulnas were processed for histomorphometry to evaluate bone formation as a 
result of mechanical loading.  
 
2.5 
In the STAT3 study, the left femurs were used to measure both bone mineral content (g) 
and bone mineral density (g/mm2). This was accomplished using peripheral dual-energy 
X-ray absorptiometry (pDXA; PIXIMus II; GE-Lunar Co.). 
Bone Mineral Content and Bone Mineral Density Measurement 
 
2.6 
In the STAT3 study, femurs were brought to room temperature over a period of 
approximately two hours in a saline bath, and mechanical testing was conducted by three-
point bending using a microforce testing machine (Vitrodyne V1000; Liveco, Inc., 
Burlington, VT). Loads were applied in the mid-diaphysis region, 10 mm apart from a 
pair of supports, in the anterposterior direction. Mechanical testing was performed at a 
cross-head speed of 0.2 mm/s. We measured ultimate force (N), stiffness (N/mm), and 
work to failure (mJ).  
Biomechanical Testing 
 
2.7 
Bone specimens were immersed in 10% neutral buffered formalin for 48 hours, then 
dehydrated in graded alcohols, cleared in xylene, then embedded in methyl methacrylate 
(MMA). Transverse thick sections (70 µm) were cut using a diamond-embedded wire 
saw (Histo-saw; Delaware Diamond Knives, Wilmington, DE). These sections were then 
Histomorphometry 
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ground down to approximately 20 µm and mounted on microscope slides. Three sections 
per limb were used for histomorphometry with a Nikon Optishot fluorescence 
microscope (Nikon, Inc., Garden City, NJ) using a Bioquant digitizing system (R&M 
Biometrics, Nashville, TN). The following primary data was collected from the periosteal 
surface at 250x magnification: total perimeter (B.Pm); single label perimeter (sL.Pm); 
double label perimeter (dL.Pm), and double label area (dL.Ar). From this primary data, 
the following quantities were derived: (mineralizing surface (MS/BS=[1/2sL.Pm + 
dL.Pm]/B/Pm x 100; %); mineral appositional rate (MAR=dL.Ar/dL.Pm/6days; µm/day) 
and bone formation rate (BFR/BS=MAR x MS/BS x 3.65; µm3/µm2/year). A set of 
relative values (rMS/BS, rMAR, and rBFR/BS) was obtained in which the nonloaded, 
internal control for each experiment was subtracted from the loaded ulna, thus 
eliminating any bone formation that occurred in that particular animal independent of 
mechanical loading. 
 
In the STAT3 study, the femurs were cut into 5µm thick frontal sections using a 
microtome (Leica, Germany). Two unstained sections were mounted onto microscope 
slides, and other sections were stained with McNeal’s tetrachrome, as well as tartrate-
resistant acid phosphatase (TRAP) to identify active osteoclasts. The following data was 
collected from the metaphyseal area at 250x magnification: tissue area (T.Ar), trabecular 
bone area (tB.Ar), trabecular bone perimeter (tB.Pm), single label perimeter (sL.Pm), 
double label perimeter (dL.Pm), double label area dL.Ar), osteoclast surface (Oc.S), and 
osteoclast number (Oc.N). From this primary data, the following quantities were derived: 
bone volume (BV/TV=tB.Ar x 100; %), mineralizing surface 
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(MS/BS=[1/2sL.Pm+dL.Pm]/B.Pm x 100; %), mineral appositional rate 
(MAR=dL.Ar/dL.Pm/6 days; µm/day), bone formation rate (BFR/BS=MAR x MS/BS x 
3.65; µm3/µm2/year), percentage of osteoclast surface (Oc.S/BS=Oc.S/tB.Pm; %), and 
osteoclast number per mm (Oc.N/Bs=Oc.N/tB.Pm; #/mm). 
 
2.8 
The pre-osteoblastic cell murine cell line, MC3T3-E1, was cultured in α-MEM (Sigma, 
St. Louis, MO, USA) containing 10% FBS (Atlanta Biologicals, Norcross, GA), 100 
U/ml penicillin G (Sigma), and 100 µg/ml streptomycin (Sigma). These cells were 
maintained in a humidified incubator containing 95% air and 5% CO2, kept at 37 degrees 
Celsius, and subcultured approximately every 72 hours. Primary osteoblasts were isolated 
from calvarial bone of 4.5-day-old STAT3 deficient mice (Col3.6-Cre;STAT3flox/flox) and 
littermate controls (Col3.6-Cre;STAT3+/+) by sequential digestions with collagenase and 
trypsin. We added 50 μg/ml ascorbic acid and cultured for 21 days to induce osteoblast 
differentiation. Then the cells were used for the measurement of ROS and NAD+/NADH 
ratio. 
Cell Culture 
 
2.9 
For fluid shear experiments, MC3T3-E1 cells or primary osteoblasts were plated on type 
I collagen-coated (10 μg/cm2, BD Biosciences, Bedford, MA) 75x38 mm2 glass slides 
(Fisher Scientific, Pittsburgh, PA) at a density of about 1 x 105 cells/cm2. The cells were 
serum-starved for 24 h in α-MEM supplemented with 0.2%FBS prior to flow. Cells were 
subjected to oscillatory fluid shear stress (12 dynes/cm2) in parallel plate flow chambers 
FSS Studies 
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at 37°C using a previously described fluid flow device (38). Hard walled tubing was used 
to connect the pump to the chamber inlet, and a reservoir was attached to the outlet to 
allow for movement of the fluid and exchange of 5% CO2. This system subjected cells to 
oscillating fluid flow at a frequency of 1 Hz in α-MEM supplemented with 0.2%FBS and 
antibiotics. Static controls were held in cell culture dishes at 37°C with 5% CO2. 
 
2.10 
Immediately after MC3T3-E1 cells were subjected to FSS for 30, 60 and 90 minutes, the 
cells were washed quickly with cold PBS (1x) and lysed with SDS lysis buffer. The lysis 
buffer contained 62.5mM Tris, 2% sodium dodecyl sulfate (SDS), 10% glycerol (v/v), 5 
mM EDTA, and 1% protease inhibitor cocktail (Sigma). After the cell lysates were boiled 
for 10 min, the protein samples were centrifuged at 14,000 g for 10 min at 4°C to remove 
any cellular debris. Protein assay was performed using a Bio-Rad detergent compatible 
(DC) protein assay. Twenty micrograms of whole cell lysates were separated by 10% 
SDS-polyacrylamide gel electrophoresis and electrotransferred to a nitrocellulose 
membrane. Membranes were blocked in Tris-buffered saline containing 5% nonfat dry 
milk and 0.1% Tween-20 (TBST), and incubated with 200 μg/ml (1:1000) rabbit anti-
STAT3 and rabbit anti-p-STAT3 (Ser 727) antibodies (Santa Cruz Biotechnology, Santa 
Cruz, CA) overnight at 4°C. Following three washes in TBST, the membranes were 
incubated with goat anti-rabbit IgG hydroperoxidase conjugated secondary antibodies 
(1:5000) for 1 h at room temperature. Immunodetection was conducted using the 
enhanced chemiluminescence (ECL) method. 
Western Blot Analysis 
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2.11 
To measure ROS in the STAT3 study, the cell-permeable dye 2,7-
dichlorodihydrofluorescein diacetate (2,7-DCF-DA) (Sigma-Aldrich), was used. Cells 
from both wild type and knockout calvarias were plated in 6 well plates in full serum 
media for 24 hours. Cells were then treated with µM H2O2 as a positive control (to 
stimulate ROS production). This was done both in the presence and absence of 50 µM 
Ag-490, a STAT3 inhibitor, for 2 hours. Cells were then suspended with 10 µM 2,7-
DCF-DA, and assayed for ROS using flow cytometry. 
Measurement of ROS 
 
2.12 
The data are expressed as mean ± SEM (standard error of the mean). Phenotypic values 
among the selected genotypes for a given sex were compared by one-way analysis of 
variance (ANOVA). Gender comparisons were performed using a two-way ANOVA 
with sex and genotype as independent variables. Differences between the loaded (right) 
and nonloaded (left) limbs were tested using paired t-tests. Statistical significance was 
assumed for p<0.05. 
Statistical Analysis 
 
22 
 
22 
CHAPTER 3. RESULTS 
A deletion of the exons 18 through 20 resulted in a conditional knockout of STAT3 
protein in the osteoblasts and osteocytes (Figure 1), which was confirmed by 
immunohistochemical staining. Note that about 10% of the STAT3 deficient mice were 
extremely small and exhibited a spine deformity, which was noticeable at age of 3-4 
weeks (Figure 2). Those mice were unable to survive longer than 8 weeks and were 
excluded in the current study. 
 
The bone phenotypes were characterized when they were 18 weeks old. Female Col3.6-
Cre;STAT3 flox/flox mice had significantly smaller body weights (-11%, p=0.02) compared 
with Col3.6-Cre;STAT3 +/+  mice, whereas the average body mass was not statistically 
different in male KO and littermate mice (Figure 3). Femur length was significantly 
shorter in the mutants for both male and female mice (Figure 4). The conditional STAT3 
KO mice exhibited low bone mass phenotype, and BMC (-13% in female, p<0.01 and -11% 
in male, p<0.05; (Figure 5) and BMD (-7% in female, p<0.05 and -12% in male, p<0.001) 
were significantly lower in KO than control littermates (Figure 6).  
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Bone histomorphometry was conducted using trabecular bones at distal femurs. For both 
female and male mice, bone volume was significantly less in KO (Col3.6-Cre;STAT3 
flox/flox) mice (-39% in female, p<0.05 and -38% in male, p<0.05; Figure 7) than their 
littermate controls. Furthermore, mineralizing surface (MS/BS, -24% in female, p<0.05 
and -29% in male, p<0.05; Figure 8), mineral appositional rate (MAR, -54% in female, 
p<0.002 and -56% in male, p<0.05, Figure 9) and bone formation rate (BFR/BS, -63% in 
female, p<0.001 and -65% in male, p<0.05; Figure 10) were significantly smaller in KO 
mice than control mice. Although the number of osteoclasts was statistically similar 
between KO mice and their control mice, osteoclast surfaces were significantly greater in 
KO mice (+39% in female and +40% in male, p<0.05; Figure 11) than their littermates. 
In order to evaluate the mechanical properties of bone in KO (Col3.6-Cre;STAT3 flox/flox) 
mice and control mice, the femurs were subject to mechanical testing. For both sexes, the 
ultimate forces (-28% in female, p<0.01 and -27% in male, p<0.01; Figure 12) and 
stiffness (-36% in female, p<0.01 and -40% in male, p<0.001; Figure 13) were reduced 
significantly in KO mice in comparison with their controls. This data suggests that 
inactivation of STAT3 specific to osteoblasts and osteocytes significantly decreases bone 
strength. Work to failure in the female mutant mice was statistically lower than in control 
females (p<0.05), while the male work to failure difference was not statistically 
significant (Figure 14). 
 
To investigate the role of STAT3 in load-driven bone formation, the Col3.6-Cre;STAT3 
flox/flox mice as well as their littermate control mice (Col3.6-Cre;STAT3 +/+) were given 
ulna loading and their bone formation responses were evaluated. The results showed that 
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load-induced bone formation was suppressed in male and female Col3.6-Cre;STAT3 
flox/flox mice. The data from female Col3.6-Cre;STAT3 flox/flox mice is shown in Figures 15 
and 16. In female mice, for instance, the relative bone formation rate (BFR/BS in the 
right ulna minus BFR/BS in the left ulna) was roughly 56% lower in Col3.6-Cre;STAT3 
flox/flox mice. This loading data support an important role of STAT3 in load-driven bone 
formation. 
 
To demonstrate the STAT3 activation in response to FSS, we examined the 
phosphorylation of STAT3 at serine 727 using MC3T3-E1 osteoblastic cells in the 
presence and absence of FSS (12 dyn/cm2). Western blotting analysis showed that serine 
phosphorylation of STAT3 increased in a manner dependent on flow duration from 30 to 
90 min (Figure 17). 
 
In order to examine if STAT3 deficiency led to an elevated level of intracellular ROS, 
calvarial osteoblasts were cultured and assayed for ROS using DCF-DA and flow 
cytometry. The ROS level was significantly higher in STAT3 deficient osteoblasts than 
control cells (Figure 18). Furthermore, administration of STAT3 inhibitor, AG490, 
significantly increased the production of ROS in control cells, but it did not affect the 
ROS level in STAT3 deficient osteoblasts. This data suggests that the inactivation of 
STAT3 both in KO osteoblasts as well as in AG-490 treated control osteoblasts increases 
the intracellular ROS level. 
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To investigate the role of oxidative stress in bone mechano-responsiveness in vivo, we 
injected female C57BL6 mice with BSO at doses of 800 and 1600 mg/kg 2 hours before 
we applied mechanical loading using an ulna loading modality with 16-week-old mice. 
Histomorphometric data demonstrated that load-induced bone formation, including 
relative label surface (rLS/BS), relative mineral appositional rate (rMAR) and relative 
bone formation rate (rBFR/BS), was dramatically suppressed in the mice pre-treated with 
both low (800 mg/kg) and high (1600 mg/kg) doses of BSO compared to the control 
treated with phosphate buffered saline (PBS) (Figures 20 & 21, a: p<0.05; b: p<0.01; c: 
p<0.001 versus PBS). These data suggest that mitochondrial activity plays an important 
role in mechanical stimulation. 
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CHAPTER 4. DISCUSSION 
The present study demonstrated that inactivation of STAT3 in osteoblasts and osteocytes 
reduced bone mass, strength, and load-driven bone formation. Furthermore, STAT3 
deficient osteoblasts presented a higher basal level of ROS, and mechanical stimulation 
failed to lower this ROS level. These results clearly show that STAT3 plays a critical role 
in bone homeostasis and mechanotransduction, and STAT3 is involved not only in load-
driven gene activation in nucleus but also in regulation of ROS and oxidative stress in 
mitochondria.  
 
Consisent with a previous study (39) our study has shown that osteoblast/osteocyte 
specific knockout of STAT3 results in an osteoporotic phenotype because of suppressed 
bone formation. We have shown that STAT3 deficiency in osteoblasts/osteocytes does 
not change the number of osteoclasts, but osteoclast surfaces were significantly greater in 
KO mice than their littermates. Since osteoclast surface is normalized by bone surface, 
there is a possibility that the greater osteoclast surfaces in STAT3 deficient mice may 
result from the reduced bone surfaces due to the inhibition of bone formation. In addition, 
our study has demonstrated that STAT3 deficiency in osteoblasts/osteocytes leads to a 
reduction in mechanical properties of mouse long bones. 
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This data suggests that STAT3 plays an important role in bone homeostasis and 
maintenance of bone strength. 
 
The difference in femur length between STAT3 knockouts and wildtype controls raises 
the question: which is responsible, bone modeling, or bone remodeling? To determine 
this, an experiment could be designed where earlier bone formation (i.e. bone modeling) 
would be differentiated from later bone formation (i.e. bone remodeling). This could be 
achieved by determining the time point where bone modeling is replaced by bone 
remodeling, and measuring the difference in femur length at both of these time points in 
conditional STAT3 knockout mice versus wildtype controls. The fact that body mass was 
affected in female conditional knockouts, and not males, suggests that estrogen and/or 
progesterone may be implicated in the role of STAT3 in load-induced bone formation. 
 
Mechanically induced bone formation was suppressed in both male and female 
conditional STAT3 KO mice. Because of the reduced mineralizing surface and mineral 
appositional rate, the result indicates that STAT3 deficiency suppresses osteoblast 
recruitment and activity. The mechanism of STAT3 activation is considered to be linked 
to the gp130 signaling pathway. Targeted disruption of the gp130 gene in mice leads to 
embryonic lethality (40). The gp130 knockout mice demonstrate defects in bone 
development, formation and resorption (5,41). Osteoblastic cells express a group of 
receptors for cytokines such as IL6 and IL11, which share the gp130 signal transducer 
(42). IL6, for instance, has been shown to be elevated in calvarial osteoblasts in response 
to mechanical stimulation (43), and IL11 is also increased in response to loading in vivo 
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as well as FSS in vitro (44). Furthermore, anti-IL11 antibody is shown to black 
mechanically induced enhancement of bone formation. Thus, is it possible that in STAT3 
KO mice gp130 signaling is blocked, impairing proliferation and differentiation of 
osteoblasts.  
 
As a downstream mechanism for STAT3-mediated bone formation, STAT3 regulates 
functions in both nuclei and mitochondria. STAT3 is activated by tyrosine 
phosphorylation, which dimerizes and translocates it to the nucleus (14). It binds specific 
gene-promoter sequences and induces gene expression (14,45-6). Furthermore, STAT3 
regulates cell respiration and metabolism in mitochondria (19,24). Without STAT3, an 
electron transport chain (ETC) is inhibited and reduction in mitochondrial activity leads 
to accumulation of ROS (45-7). Therefore, inhibition of bone formation in the conditional 
STAT3 KO mice may result from the suppression of gene expression and elevation of 
ROS in osteoblasts.  
 
Regarding gene regulation in nucleus, disruption of STAT3 likely alters expression of 
mechanosensitive genes such as Wnt molecules. In stromal cells transforming growth 
factor (TGF)-β mediated inhibition of Wnt3a is in part through the suppression of STAT3 
(48). 
 
Our unpublished data as indicate that STAT3 regulates expression of Wnt5a in 
osteoblasts. Both Wnt3a and Wnt5a have previously shown to stimulation osteoblast 
proliferation and differentiation (49-50). Using the conditional STAT3 deficient mice in 
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this study, our future study may include identification of load-drive up-stream genes in 
the presence and absence of STAT3 in osteoblasts. 
 
It has been known that accumulation of ROS is associated with osteoporosis and aging 
related bone loss. Recently, STAT3 has been shown to connect mitochondrial functions 
to ROS production in hepatocytes and cardiomyocytes (24). In order to investigate 
whether STAT3 inactivation would regulate the ROS level and mitochondrial functions 
in osteoblasts, we applied FSS on STAT3 deficient calvarial osteoblasts. First, we 
showed that serine phosphorylation of STAT3 increased from 30 to 90 min following 
FSS, suggesting the sustained STAT3 activation in response to mechanical stimulation. 
Especially, the conserved serine phosphorylation site on STAT3 is critical in regulation 
of mitochondrial activities (24). Next, we demonstrated STAT3-driven association of the 
level of ROS through mitochondrial activity with the effects of mechanical loading on 
bone formation. The result presented a significant increase in ROS in STAT3 deficient 
osteoblasts. Furthermore, FSS reduced the level of ROS through stimulation of 
mitochondrial activity but it failed to do so in STAT3 deficient osteoblasts. Clinical 
evidence suggests that age related bone loss is closely associated with oxidative stress 
(51-4). In addition, recent studies have demonstrated that oxidative stress antagonizes 
Wnt signaling (3,55). It has yet to be tested whether reduction in load-driven bone 
formation in STAT3 KO mice is in part caused by an increase in the basal level of ROS 
and/or insensitivity of ROS levels in response to mechanical loading. 
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In order to further investigate the role of oxidative stress in bone mechano-responsiveness 
in vivo, we injected female C57BL6 mice with BSO at doses of 800 and 1600 mg/kg 2 
hours before we applied mechanical loading using an ulna loading modality with 16-
week-old mice. The histomorphometric data demonstrated that load-induced bone 
formation, including relative label surface (rLS/BS), relative mineral appositional rate 
(rMAR) and relative bone formation rate (rBFR/BS), was dramatically suppressed in the 
mice pre-treated with both low (800mg/kg) and high (1600 mg/kg) doses of BSO 
compared to the control treated with phosphate buffered saline (PBS). This data suggests 
that mitochondrial activity plays an important role in mechanical stimulation in vivo. 
 
In the current study, both osteoblasts and osteocytes are deficient in STAT3. It has been 
proposed that osteocytes are mechanosensing cells in bone. Thus, there is a possibility 
that suppression of load-driven bone formation in this study is primarily caused by 
STAT3 deficiency in osteocytes. Future studies using osteocyte specific inactivation of 
STAT3 might further differentiate the role of STAT3 in osteoblasts and osteocytes.  
 
In conclusion, loss-of-function mutations of STAT3 reduce bone mass and load-driven 
anabolic responses, and STAT3 plays a critical role in regulation of anabolic pathways in 
the nucleus as well as suppression of ROS in mitochondria. 
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Figure 1: Floxed STAT3 DNA. 
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Figure 2: Appearance of the conditional STAT3 KO mice. 
  
40 
 
32 
 
 
Figure 3: Body mass comparison. 
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Figure 4: Comparison of femur length. 
  
42 
 
32 
 
 
Figure 5: Comparison of bone mineral content. 
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Figure 6: Comparison of bone mineral density. 
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Figure 7: Comparison of bone volume. 
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Figure 8: Comparison of mineralizing surface. 
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Figure 9: Comparison of mineral appositional rate. 
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Figure 10: Comparison of bone formation rate. 
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Figure 11: Comparison of osteoclast surface. 
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Figure 12: Comparison of ultimate force. 
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Figure 13: Comparison of stiffness. 
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Figure 14: Comparison of work to failure. 
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Figure 15: Comparison of midshaft ulnar sections. 
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Figure 16: rMS/BS, rMAR, rBFR/BS. 
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Figure 17: Serine phosphorylation of STAT3 in response to FSS. 
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Figure 18: Flow cytometric analysis of ROS level. 
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Figure 19: NAD+/NADH ratios. 
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Figure 20: Midshaft ulnar sections – BSO versus control. 
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Figure 21: rMS/BS, rMAR, rBFR/BS – BSO versus control.  
